de Moraes Junior Rm, Mota Gs, Carolino Mlo, Kerche-Silva Le
{"title":"基因突变和人源化单克隆抗体治疗小细胞肺癌的研究进展","authors":"de Moraes Junior Rm, Mota Gs, Carolino Mlo, Kerche-Silva Le","doi":"10.4172/2576-1447.1000S1-013","DOIUrl":null,"url":null,"abstract":"Small-cell lung cancer (SCLC) is one of the deadliest type of cancer with fast tumor growth and rapid metastatic dissemination. The most common genetic modifications associated with SCLC is connected to tumor suppressor and oncogenic genes, genes that control the cycle arrest of the cells. Standard treatment for SCLC is a combination of drugs such as cisplatin and etoposide and sometimes radiotherapy of the chest can be used. But these treatments have not been sufficient to decrease dead rate in SCLC patients and new drugs have been studied, specially humanized monoclonal antibodies (mAb). Therefore, the aim of this work is to review the main genetic alterations in SCLC and the mAb that has been tested to improve life expectancy in these patients.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"2 1","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2017-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Genetic Mutations and Humanized Monoclonal Antibody Treatment in Small-Cell Lung Cancer: A Review\",\"authors\":\"de Moraes Junior Rm, Mota Gs, Carolino Mlo, Kerche-Silva Le\",\"doi\":\"10.4172/2576-1447.1000S1-013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Small-cell lung cancer (SCLC) is one of the deadliest type of cancer with fast tumor growth and rapid metastatic dissemination. The most common genetic modifications associated with SCLC is connected to tumor suppressor and oncogenic genes, genes that control the cycle arrest of the cells. Standard treatment for SCLC is a combination of drugs such as cisplatin and etoposide and sometimes radiotherapy of the chest can be used. But these treatments have not been sufficient to decrease dead rate in SCLC patients and new drugs have been studied, specially humanized monoclonal antibodies (mAb). Therefore, the aim of this work is to review the main genetic alterations in SCLC and the mAb that has been tested to improve life expectancy in these patients.\",\"PeriodicalId\":90901,\"journal\":{\"name\":\"Journal of lung cancer\",\"volume\":\"2 1\",\"pages\":\"1-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of lung cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2576-1447.1000S1-013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of lung cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2576-1447.1000S1-013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Genetic Mutations and Humanized Monoclonal Antibody Treatment in Small-Cell Lung Cancer: A Review
Small-cell lung cancer (SCLC) is one of the deadliest type of cancer with fast tumor growth and rapid metastatic dissemination. The most common genetic modifications associated with SCLC is connected to tumor suppressor and oncogenic genes, genes that control the cycle arrest of the cells. Standard treatment for SCLC is a combination of drugs such as cisplatin and etoposide and sometimes radiotherapy of the chest can be used. But these treatments have not been sufficient to decrease dead rate in SCLC patients and new drugs have been studied, specially humanized monoclonal antibodies (mAb). Therefore, the aim of this work is to review the main genetic alterations in SCLC and the mAb that has been tested to improve life expectancy in these patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
